CLYM

Business Context and Reporting Period

Company: Climb Bio, Inc. (Nasdaq: CLYM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. The company's pipeline consists of two primary product candidates: budoprutug, an anti-CD19 monoclonal antibody for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE); and CLYM116, an anti-APRIL monoclonal antibody for IgA Nephropathy (IgAN). The company has no approved products and has not generated any product revenue.

Key Financial Metrics

Note: 2024 results included a one-time non-cash charge of $51.7 million for acquired in-process research and development (IPR&D) related to the acquisition of Tenet Medicines, Inc.

Material Changes vs. Prior Period

• R&D Expense Increase: R&D expenses increased by $32.4 million (226%) year-over-year. This was driven by the advancement of clinical trials for budoprutug (pMN, ITP, SLE) and the initiation of the CLYM116 program, which included a $9.0 million upfront payment to Mabworks in January 2025.
• Net Loss Improvement: Net loss decreased by $14.0 million compared to 2024. This improvement is primarily attributable to the absence of the $51.7 million non-cash IPR&D charge recorded in 2024, partially offset by higher operating expenses in 2025.
• Acquisition Impact: The 2024 acquisition of Tenet Medicines, Inc. (completed June 2024) brought budoprutug into the portfolio. 2025 expenses reflect the full-year development costs of this asset, whereas 2024 only included partial-year costs plus the acquisition charge.
• Stock Activity: In December 2025, the company entered into an exchange agreement where a major shareholder exchanged 20.4 million shares of common stock for a pre-funded warrant, reducing the outstanding share count to approximately 47.8 million.

Guidance, Outlook, and Risks

Outlook and Guidance

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities of $160.7 million are sufficient to fund operations into 2028.
• Clinical Milestones:
  • Budoprutug: First patient dosed in the Phase 2 PrisMN trial (pMN) in November 2025. Initial data from the low-dose cohort expected in H2 2026. Phase 1b trials in ITP and SLE are ongoing. A Phase 1 trial of the subcutaneous (SC) formulation in healthy volunteers was completed in Australia in September 2025, with data expected in H1 2026.
  • CLYM116: Phase 1 trial in healthy volunteers initiated in November 2025. Initial data expected in mid-2026.

Material Risks and Contingencies

• Internal Controls: The company identified two unremediated material weaknesses in internal control over financial reporting as of December 31, 2025, related to the control environment and lack of formal accounting policies. Management is implementing remediation efforts.
• Legal Proceedings: On December 31, 2025, Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin regarding a dispute over the Asset Purchase Agreement. The company seeks a declaratory judgment that budoprutug is not a "Product" under the agreement and that no milestone payment is owed.
• Capital Requirements: The company expects to continue incurring substantial losses and will require additional capital to fund operations beyond 2028. Future funding may involve equity offerings, debt, or collaborations, which could result in dilution.
• Regulatory and Development Risk: As a clinical-stage company, success depends on regulatory approval and clinical trial outcomes. There is no guarantee that budoprutug or CLYM116 will achieve regulatory approval or commercial success.

Key Facts for Investor Verification

• Cash Runway: Verify the $160.7 million cash position and the assumption that it funds operations into 2028, given the high burn rate of clinical-stage biotech.
• Legal Dispute: Monitor the status of the litigation against Acelyrin/Alumis regarding the budoprutug milestone payment obligation, as this could impact future cash outflows.
• Internal Controls: Track the remediation progress of the material weaknesses in internal controls over financial reporting, as failure to remediate could impact future reporting reliability and investor confidence.
• Clinical Data Readouts: Watch for the release of Phase 1 data for the budoprutug SC formulation (H1 2026) and initial Phase 2 data for budoprutug in pMN (H2 2026), which are critical value drivers.
• License Obligations: Review the potential future milestone and royalty payments under the Acelyrin, CRH, ProBioGen, and Mabworks agreements, which could total hundreds of millions of dollars upon commercial success.